SARS-CoV-2 Omicron variant, COVID-19, vaccination, primary series, booster, vaccine effectiveness
Clostridioides difficile, inflammatory bowel disease, cost-effectiveness analysis, economic evaluation, fecal microbiota transplantation, vancomycin, fidaxomicin.
COVID-19, Vaccine, Heterologous booster, Third dose, Immunogenicity, safety